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Reply: P2Y12-Based Platelet Function
Assays Should be Complemented
With Cyclooxygenase-Dependent
Testing in Framing the
Therapeutic Windows for Dual
Antiplatelet Therapy
We thank Drs. Gasparovic and Petricevic for their interest in our
study (1) and their comments. They strongly suggest that P2Y12-
based platelet function assays should be complemented with cyclo-
oxygenase-dependent testing in framing the therapeutic windows for
dual antiplatelet therapy. We think that this statement is highly
speculative and not supported by the available evidence. Indeed,
aspirin resistance has been extensively discussed as a real entity by
itself and its association with clinical outcomes. First, response to
aspirin assessed by cyclooxygenase-dependent testing has probably
been overestimated due to a problem of compliance, and a previous
study by our group showed that noncompliance was the main
explanation for aspirin resistance, being a rare entity in compliant
patients (2). For ischemic risk, some studies suggest the potential
impact of aspirin resistance on ischemic events (3), but a recent study
assessing the beneﬁt of tailored therapy based on platelet testing of
aspirin response failed to show any signiﬁcant beneﬁt (4). Therefore,
testing aspirin response for ischemic prognosis and increasing aspirin
dose on the basis of the test results is not supported by available ev-
idence. For bleeding risk, as assessed in our study, to our knowledge,
no study has ever linked the variability of aspirin response and
bleeding complications in patients undergoing percutaneous coro-
nary intervention after acute coronary syndrome. Therefore, the
proposal in their letter is not in line with current data available on
platelet monitoring. Also, themajor risk of assessing aspirin response
could be to use a higher dose in some patients, whereas recent evi-
dence clearly showed that a high dose of aspirin does not provide any
ischemic beneﬁt, only a constant increase in bleeding and gastroin-
testinal events (5).
Accordingly, we performed an additional analysis to conﬁrm
previous assumptions. In the present study, aspirin response was
assessed by arachidonic acid–induced platelet aggregation (AA-Ag).
The rate of aspirin resistance was very low, with only 60 patients
(4%) with aspirin resistance deﬁned as AA-Ag above the 30%
threshold previously proposed. We did not observe any relationship
between AA-Ag and the occurrence of bleeding complications in
our population, as suggested by Gasparovic et al. This could also be
explained by the biological proﬁle of aspirin response in 1,082
patients (70%) of patients with AA-Ag ¼ 0%. Indeed, to identify apredictor of bleeding with platelet monitoring, we need to deﬁne
hyperresponse, which is probably impossible with a drug providing 0%
in more than two thirds of the patients with the present test.
We appreciate the suggestions of Drs. Gasparovic and Petricevic;
however, this statement is supported neither by available evidence nor
by the new analysis provided in this letter. Therefore, it was not an
omission, and we believe that does not compromise the robustness of
the presented data. Following the proposal to integrate the aspirin
effect into bleeding risk assessment, the next step might be to use the
new P2Y12 blockers as long-term monotherapy without aspirin as
currently tested in the GLOBAL LEADERS study
(NCT01813435).
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Looking for the Native Annulus
After Transcatheter Aortic Valve
Replacement?
I readwith great interest the recently publishedpaperbyBinder et al. (1)
that described the impact of post-implantation SAPIENXT (Edwards
Lifesciences Inc., Irvine, California) geometry and positioning on
clinical outcome after transcatheter aortic valve replacement (TAVR).
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109The main ﬁnding of the authors is that low implantation depth is
associated with clinically signiﬁcant new conduction disturbances and
permanent pacemaker implantation. Although this result was previ-
ously reported by our team (2), the authors should be congratulated
because the statistical power of their study is much better than ours (89
vs. 34 patients). However, the methodology for measuring the primary
endpoint (i.e., the implantation depth of the stent with multidetector
computed tomography), raises some questions. Indeed, the authors
explained at the end of theMethods section that “the distance from the
stent frame inﬂow to the aortic annulus (most basal insertion of the
native aortic leaﬂets) was measured.”A proper assessment of the native
annulus beforeTAVR is already a difﬁcult and a still debated challenge;
therefore, a proper assessment after TAVR seems very difﬁcult or
unfeasible. Indeed,whenwemade thesemeasurements in our study (2),
we clearly noted that post-implantation multi-detector computed to-
mography implies a complexmixture of artifacts associated with native
calciﬁcations and stent frame, particularly at the most basal insertion of
thenative aortic leaﬂets,which is not visible exceptwhen the stent frame
is implanted in a high position. This is the reasonwhy the implantation
depth was evaluated in our study with reference to the ﬂoor of the si-
nuses of Valsalva.
Because this endpoint reﬂects the main result of their study, I
think that the authors should precisely state, with a dedicated
ﬁgure, the methodology used to measure the depth of implantation
to ensure good reproducibility and comparability with previous and
future studies on this interesting topic.
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Reply: Looking for the Native Annulus
After Transcatheter Aortic Valve
Replacement?
We thankDr. Caudron for his interest in our paper (1) that evaluated
post-deployment geometry and its impact on conduction distur-
bances, hemodynamic performance, and paravalvular regurgitation.
We have also readwith great interest hismany previous contributions
to the ﬁeld. Dr. Caudron raises concerns regarding the difﬁculty inevaluating the location of the aortic annulus/aortic valve ventricular
plane on post–transcatheter aortic valve implantation (TAVI)
multidimensional computed tomography (CT) imaging and raises
questions as to the strength of the ﬁndings of our study. In fact, Dr.
Caudron implies that even the native annulus may not be repro-
ducibly evaluated on pre-procedural CT: “Aproper assessment of the
native annulus before TAVI is already a difﬁcult and still debated
challenge.” We respectfully disagree with this sentiment. We and
other groups (2–4) have for the last 5 years consistently shown that
the basal ring and annular geometry can be evaluated in a granular and
reproducible fashion prior to TAVI. These 3-dimensional mea-
surements of the annulus have been shown to display high intraclass
correlation coefﬁcients in multiple studies and have received
consensus support to be used to assist transcatheter heart valve se-
lection. Importantly, these measurements have not only been
conﬁrmed to be reproducible, they have also been shown to be
invaluable in guiding transcatheter heart valve sizing and have
allowed the improvement in TAVI-related clinical outcomes (5,6).
With regard to the issue of localization of the annular plain
on post-TAVI imaging, we agree that with only post-TAVI CT
imaging this is very difﬁcult and would undoubtedly suffer from
reproducibility issues. However, unlike in Caudron et al. (7), we
were not limited to post-TAVI CT imaging but rather had both pre-
and post-transcatheter aortic valve replacement CT imaging for all
cases. The baseline CT imaging prior to TAVI provided us an
important mask to allow for the identiﬁcation of the aortic valve
ventricular plane on the pre-transcatheter aortic valve replacement
CT exam and to colocalize it on the post-TAVI CT. Although we
did not perform formal reproducibility analyses, as there was only 1
reader of all of these studies, we strongly feel that the methodological
differences in our study with pre- and post-TAVI CT imaging are
real strengths of our analysis and afforded us a unique opportunity to
perform the measurements and analyses presented in our paper (1).
*Jonathon Leipsic, MD
Ronald K. Binder, MD
John G. Webb, MD
*St. Paul’s Hospital
1081 Burrard Street
V6Z 1Y6, Vancouver
British Columbia
Canada
E-mail: jleipsic@providencehealth.bc.ca
http://dx.doi.org/10.1016/j.jcin.2013.10.010
Please note: Drs. Leipsic, Binder, and Webb are consultants to Edwards Lifesciences. Dr. Binder has
received unrestricted research grants from the Swiss National Foundation.REFERENCES
1. Binder RK, Webb JG, Toggweiler S, et al. Impact of post-implant
Sapien XT geometry and position on conduction disturbances, hemo-
dynamic performance, and paravalvular regurgitation. J Am Coll Cardiol
Intv 2013;6:462–8.
2. Willson AB, Webb JG, Labounty TM, et al. 3-dimensional aortic annular
assessment by multidetector computed tomography predicts moderate or
severe paravalvular regurgitation after transcatheter aortic valve replacement:
a multicenter retrospective analysis. J Am Coll Cardiol 2012;59:1287–94.
